Treatment Research Initiative to Cure ALS October 2022 NEWS RELEASE Nevrargenics participates in the first TRICALS workshop at Schiphol, Netherlands, on ALS since the COVID pandemic.
Iniation of efficacy studies on MS and ALS September 2022 NEWS RELEASE Nevrargenics launches efficacy studies on MS and ALS models through Experimentica and Charles River respectively.
Interview of our CEO on Beyond Biotech podcast August 2022 Podcast Link CEO Andy Whiting gives an interview to Liza Laws, Senior Editor of Labiotech about neurodegeneration and Nevrargenics's drugs.
Collaboration with King’s College in Parkinson’s June 2022 NEWS RELEASE Research collaboration launch with Professor Susan Duty at King’s College, looking the application of our drugs in Parkinson’s disease models.
Nevrargenics own premises June 2022 Nevrargenics acquires its own premises for the development of its offices and laboratories on Mandale Park in Durham.
Lead drug candidate safety studies of completed March 2022 Two (once weekly and twice weekly dosing), 28 day tox studies were completed on NVG0645 showing a potential therapeutic window.
Nevrargenics drug candidate provides neuroprotection in Parkinson’s model September 2021 NEWS RELEASE Nevrargenics reports that lead drug candidate provides neuroprotection in a 6-hydroxydopamine model of Parkinson’s disease.
Neuro-restorative and protective effects of drug NVG0645 presented December 2020 NEWS RELEASE Nevrargenics reports multi-neuro-restorative and protective effects using lead drug as a new therapeutic strategy for ALS.